ReviewAllergologie select2021
Janus kinase inhibitors for the therapy of atopic dermatitis.
Review in Allergologie select, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib.Dermatology and therapy · 2026Article
- Tryptanthrin Nanoliposomal Lotion as a Corticosteroid-Free Strategy for Safe and Effective Treatment of Atopic Dermatitis.Biomaterials research · 2026Article
- Real-World Use of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Single-Centre Retrospective Descriptive Analysis.Clinical, cosmetic and investigational dermatology · 2026Article
- Allergic Contact Dermatitis: Immunopathology and Potential Therapeutic Strategies.Journal of clinical medicine · 2025Review
- Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- A genome-wide pleiotropy study between atopic dermatitis and neuropsychiatric disorders.Human genomics · 2025Article
- Infections in Patients with Atopic Dermatitis and the Influence of Treatment.American journal of clinical dermatology · 2025Review
- Review
- Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema.Pharmaceutics · 2024Article
- Topical Prescription Management.Advances in experimental medicine and biology · 2024Review
- T helper cell 17/regulatory T cell balance regulates ulcerative colitis and the therapeutic role of natural plant components: a review.Frontiers in medicine · 2024Review
- "De Novo" Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature.Journal of clinical medicine · 2023Review
- A concept for integrated care pathways for atopic dermatitis-A GAClinical and translational allergy · 2023Review
- Quantifying Inflammatory Response and Drug-Aided Resolution in an Atopic Dermatitis Model with Deep Learning.The Journal of investigative dermatology · 2023Article
- Human umbilical cord mesenchymal stem cell treatment alleviates symptoms in an atopic dermatitis-like mouse model.Stem cell research & therapy · 2023Article
- Novel Therapeutic Targets for the Treatment of Atopic Dermatitis.Biomedicines · 2023Review
- How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?International journal of molecular sciences · 2023Review
- Recalcitrant nodular scabies showing excellent response to tofacitinib: five case reports.Therapeutic advances in chronic disease · 2023Article
- Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study.Dermatology and therapy · 2022Article
- The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual receptor-associated kinases, thereby preventing the mediation of inflammatory signals. Several JAK inhibitors with varying mechanism of action, potency, and safety represent potential therapeutic options for AD in both topical and systemic application. The JAK1/2 selective JAK inhibitor baricitinib was the first substance from this class of drugs approved by the EMA for the systemic oral treatment of AD. The clinical development program of the JAK1 selective inhibitors upadacitinib and abrocitinib is finalized with positive results for AD. The PAN-JAK inhibitor delgocitinib was the first substance being approved for the treatment of AD (in Japan). This review article covers the rising data on investigational and approved JAK inhibitors in the context of the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.